Apellis Pharmaceuticals logged a 1.7% change during today's evening session, and is now trading at a price of $64.04 per share. The S&P 500 index moved 1.0%. APLS's trading volume is 1,887,771 compared to the stock's average volume of 2,390,050.
Apellis Pharmaceuticals trades -13.17% away from its average analyst target price of $73.75 per share. The 16 analysts following the stock have set target prices ranging from $44.0 to $95.0, and on average have given Apellis Pharmaceuticals a rating of buy.
Anyone interested in buying APLS should be aware of the facts below:
-
Apellis Pharmaceuticals has moved 27.0% over the last year, and the S&P 500 logged a change of 17.0%
-
Based on its trailing earnings per share of -5.23, Apellis Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of -12.2 while the S&P 500 average is None
-
APLS has a forward P/E ratio of -39.3 based on its forward 12 month price to earnings (EPS) of $-1.63 per share
-
The company has a price to earnings growth (PEG) ratio of -0.41 — a number near or below 1 signifying that Apellis Pharmaceuticals is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 32.64 compared to its sector average of None
-
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
-
Based in Waltham, the company has 767 full time employees and a market cap of $7.59 Billion.